Patents by Inventor Lieven Stuyver
Lieven Stuyver has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7157226Abstract: The present invention relates to a polynucleic acid composition comprising or consisting of at least one polynucleic acid containing 8 or more contiguous nucleotides corresponding to a nucleotide sequence from the region spanning positions 417 to 957 of the Core/E1 region of HCV type 3; and/or the region spanning positions 4664 to 4730 of the NS3 region of HCV type 3; and/or the region spanning positions 4892 to 5292 of the NS3/4 region of HCV type 3; and/or the region spanning positions 8023 to 8235 of the NS5 region of the BR36 subgroup of HCV type 3a; and or the coding region of HCV type 4a starting at nucleotide 379 in the core region; and/or the coding region of HCV type 4; and/or the coding region of HCV type 5, with said nucleotide numbering being with respect to the numbering of HCV nucleic acids as shown in Table 1, and with said polynucleic acids containing at least one nucleotide difference with known HCV type 1, and/or HCV type 2 genomes in the above-indicated regions, or the complement thereof.Type: GrantFiled: April 27, 1994Date of Patent: January 2, 2007Assignee: Innogenetics S.A.Inventors: Geert Maertens, Lieven Stuyver
-
Patent number: 7129337Abstract: The present invention relates to new genomic nucleotide sequences and amino acid sequences corresponding to the coding region of these genomes. The invention relates to new HCV types and subtypes sequences which are different from the known HCV types and subtypes sequences. More particularly, the present invention relates to new HCV type 7 sequences, new HCV type 9 sequences, new HCV type 10 and new HCV type 11 sequences. Also, the present invention relates to new HCV type 1 sequences of subtypes 1d, 1e, 1f and 1g; new HCV type 2 sequences of subtypes 2e, 2f, 2g, 2h, 2i, 2k and 2l; new HCV type 3 sequences of subtype 3g, new HCV type 4 sequences of subtypes 4k, 4l and 4m; a process for preparing them, and their use for diagnosis, prophylaxis and therapy. More particularly, the present invention provides new type-specific sequences of the Core, the E1 and the NS5 regions of new HCV types 7, 9, 10 and 11, as well as of new variants (subtypes) of HCV types 1, 2, 3 and 4.Type: GrantFiled: October 23, 1995Date of Patent: October 31, 2006Assignee: Innogenetics N.V.Inventors: Geert Maertens, Lieven Stuyver
-
Patent number: 7122306Abstract: The present application provides polynucleic acid sequences of 8 or more contiguous nucleotides selected from an HCV subtype 3c genomic sequence selected from the region spanning positions 1 to 957 of the Core of Core/E1 region of HCV subtype 3c, wherein said polynucleic acid sequence is capable of hybridizing to HCV type 3c, but not another type or subtype of HCV; or the complement of the polynucleic acid, wherein the polynucleic acid contains at least one genotype-specific nucleotide. Methods and means of using and making the described sequences are also provided.Type: GrantFiled: June 5, 2001Date of Patent: October 17, 2006Assignee: N.V. Innogenetics S.A.Inventors: Geert Maertens, Lieven Stuyver
-
Patent number: 6974864Abstract: The present invention relates to new genomic nucleotide sequences and amino acid sequences corresponding to the coding region of these genomes. The invention relates to new HCV types and subtypes sequences which are different from the known HCV types and subtypes. More particularly, the present invention relates to new HCV type 7 sequences, new HCV type 9 sequences, new HCV type 10 and new HCV type 11 sequences. Also, the present invention relates to new HCV type 1 sequences of subtypes 1d, 1e, 1f and 1g; new HCV type 2 sequences of subtypes 2e, 2f, 2g, 2h, 2I, 2k and 2l; new HCV type 3 sequences of subtype 3g, new HCV type 4 sequences of subtypes 4k, 4l and 4m; a process for preparing them, and their use for diagnosis, prophylaxis and therapy. More particularly, the present invention provides new type-specific sequences of the Core, the E1 and the NS5 regions of new HCV types 7, 9, 10 and 11, as well as of new variants (subtypes) of HCV types 1, 2, 3 and 4.Type: GrantFiled: May 9, 2001Date of Patent: December 13, 2005Assignee: Innogenetics N.V.Inventors: Geert Maertens, Lieven Stuyver
-
Publication number: 20050175990Abstract: The present invention relates to a method for detection and/or genetic analysis of HBV in a biological sample, comprising hybridizing the polynucleic acids of the sample with a combination of at least two nucleotide probes, with said combination hybridizing specifically to a mutant target sequence chosen from the HBV RT pol gene region and/or to a mutant target sequence chosen from the HBV preCore region and/or to a mutant target sequence chosen from the HBsAg region of HBV and/or to a HBV genotype-specific target sequence, with said target sequences being chosen from FIG.Type: ApplicationFiled: June 27, 2003Publication date: August 11, 2005Inventors: Lieven Stuyver, Rudi Rossau, Geert Maertens
-
Patent number: 6891026Abstract: The invention relates to a process for genotyping any HCV isolate present in a biological sample, previously identified as being HCV positive, and for classifying said isolate according to the percentage of homology with other HCV isolates, comprising the steps of: contacting said sample in which the ribonucleotides or deoxyribonucleotides have been made accessible, if need be, under suitable denaturation, with at least one probe from about 10 to about 40 nucleotides, with said probe being liable to hybridize to a region being in the domain extending from nucleotide at position ?291 to nucleotide at position ?66 of the 5? untranslated region of one of the HCV isolates represented by their cDNA sequences, with said numbering of position beginning with the first ATG codon of the open reading frame encoding the HCV polyprotein, or with said probe being complementary to the above-defined probes, detecting the complexes possibly formed between said probe and the nucleotide sequence of the HCV isolate to be idenType: GrantFiled: July 6, 2001Date of Patent: May 10, 2005Assignee: Innogenetics N.V.Inventors: Geert Maertens, Lieven Stuyver, Rudi Rossau, Hugo Van Heuverswyn
-
Patent number: 6887985Abstract: The invention relates to a process for genotyping any HCV isolate present in a biological sample, previously identified as being HCV positive, and for classifying said isolate according to the percentage of homology with other HCV isolates, comprising the steps of: contacting said sample in which the ribonucleotides or deoxyribonucleotides have been made accessible, if need be, under suitable denaturation, with at least one probe from about 10 to about 40 nucleotides, with said probe being liable to hybridize to a region being in the domain extending from nucleotide at position ?291 to nucleotide at position ?66 of the 5? untranslated region of one of the HCV isolates represented by their cDNA sequences, with said numbering of position beginning with the first ATG codon of the open reading frame encoding the HCV polyprotein, or with said probe being complementary to the above-defined probes, detecting the complexes possibly formed between said probe and the nucleotide sequence of the HCV isolate to be idenType: GrantFiled: July 6, 2001Date of Patent: May 3, 2005Assignee: Innogenetics N.V.Inventors: Geert Maertens, Lieven Stuyver, Rudi Rossau, Hugo Van Heuverswyn
-
Publication number: 20050049220Abstract: An anti-hepatitis C agent which is an anti-metabolite to the host and cannot be administered on a daily or chronic basis as is usual in anti-viral therapy (referred to below as an “anti-HCV anti-metabolite”), can be administered using a traditional anti-cancer dosing regimen (for example via intravenous or parenteral injection), over a period of one, two, three, four, five, six, or seven days followed by cessation of therapy until rebound of the viral load is noted. This dosing regimen runs counter to conventional antiviral experience, wherein effective agents are usually administered over at least fourteen days of sustained therapy, and typically on an indefinite daily basis.Type: ApplicationFiled: August 18, 2004Publication date: March 3, 2005Inventor: Lieven Stuyver
-
Publication number: 20050049204Abstract: The disclosed invention is a composition for and a method of treating a Flaviviridae infections, such as bovine viral diarrhea virus (“BVDV”), Dengue Virus (DENV), West Nile Virus (WNV) and hepatitis C virus (HCV), as well as abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(V) or N-(phosphonoacetyl)-L-aspartate (PALA), or a pharmaceutically acceptable salt or prodrug thereof.Type: ApplicationFiled: March 29, 2004Publication date: March 3, 2005Inventors: Michael Otto, Lieven Stuyver
-
Publication number: 20040266723Abstract: The disclosed invention is a composition for and a method of treating Flaviviridae (Hepacivirus, Flavivirus, Pestivirus) infections, including BVDV and HCV, in a host, including animals, and especially humans, using a small molecule or its pharmaceutically acceptable salt or prodrug.Type: ApplicationFiled: December 17, 2001Publication date: December 30, 2004Inventors: Michael J. Otto, Kyoichi A. Watanabe, Steve Patterson, Krysztof W. Pankiewicz, Lieven Stuyver
-
Patent number: 6803187Abstract: The present invention relates to a method for the rapid and reliable detection of drug-selected mutations in the HIV protease gene allowing the simultaneous charaterization of a range of codons involved in drug resistance using specific sets of probes optimized to function together in a reverse-hybridization assay.Type: GrantFiled: June 25, 2001Date of Patent: October 12, 2004Assignee: Innogenetics N.V.Inventor: Lieven Stuyver
-
Publication number: 20040191768Abstract: The invention relates to a process for genotyping any HCV isolate present in a biological sample, previously identified as being HCV positive, and for classifying said isolate according to the percentage of homology with other HCV isolates, comprising the steps of:Type: ApplicationFiled: April 13, 2004Publication date: September 30, 2004Applicant: INNOGENETICS, S.A.Inventors: Geert Maertens, Lieven Stuyver, Rudi Rossau, Hugo Van Heuverswyn
-
Patent number: 6762024Abstract: The present invention relates to a polynucleic acid composition comprising or consisting of at least one polynucleic acid containing 8 or more contiguous nucleotides corresponding to a nucleotide sequence from the region spanning positions 417 to 957 of the Core/E1 region of HCV type 3; and/or the region spanning positions 4664 to 4730 of the NS3 region of HCV type 3; and/or the region spanning positions 4892 to 5292 of the NS3/4 region of HCV type 3; and/or the region spanning positions 8 023 to 8 235 of the NS5 region of the BR36 subgroup of HCV type 3a; and/or the coding region of HCV type 4a starting at nucleotide 379 in the core region; and/or the coding region of HCV type 4; and/or the coding region of HCV type 5, with said nucleotide numbering being with respect to the numbering of HCV nucleic acids as shown in Table 1, and with said polynucleic acids containing at least one nucleotide difference with known HCV type 1, and/or HCV type 2 genomes in the above-indicated regions, or the complement thereof.Type: GrantFiled: June 12, 2001Date of Patent: July 13, 2004Assignee: Innogenetics, S.A.Inventors: Geert Maertens, Lieven Stuyver
-
Patent number: 6713251Abstract: The present invention relates to a method for the rapid and reliable detection of drug-induced mutations in the reverse transcriptase gene allowing the simultaneous characterization of a range of codons involved in drug resistance using specific sets of probes optimized to function together in a reverse-hybridization assay.Type: GrantFiled: August 31, 2001Date of Patent: March 30, 2004Assignee: Innogenetics N.V.Inventors: Lieven Stuyver, Joost Louwagie, Rudi Rossau
-
Patent number: 6709812Abstract: The present invention relates to a method for detection and/or genetic analysis of HBV in a biological sample, comprising hybridizing the polynucleic acids of the sample with a combination of at least two nucleotide probes, with said combination hybridizing specifically to a mutant target sequence chosen from the HBV RT pol gene region and/or to a mutant target sequence chosen from the HBV preCore region and/or to a mutant target sequence chosen from the HBsAg region of HBV and/or to a HBV genotype-specific target sequence, with said target sequences being chosen from FIG.Type: GrantFiled: October 8, 1998Date of Patent: March 23, 2004Assignee: Innogenetics N.V.Inventors: Lieven Stuyver, Rudi Rossau, Geert Maertens
-
Publication number: 20040029110Abstract: The present invention relates to a method for detection and/or genetic analysis of HBV in a biological sample, comprising hybridizing the polynucleic acids of the sample with a combination of at least two nucleotide probes, with said combination hybridizing specifically to a mutant target sequence chosen from the HBV RT pol gene region and/or to a mutant target sequence chosen from the HBV preCore region and/or to a mutant target sequence chosen from the HBsAg region of HBV and/or to a HBV genotype-specific target sequence, with said target sequences being chosen from FIG.Type: ApplicationFiled: June 4, 2003Publication date: February 12, 2004Applicant: INNOGENETICS N.V.Inventors: Lieven Stuyver, Rudi Rossau, Geert Maertens
-
Publication number: 20030124512Abstract: This invention pertains to a novel method to screen the efficacy of various anti-viral, and especially anti-HIV and HCV agents by using a novel real-time polymerase chain reaction technique. This method can also be applied to toxicity screening, especially of mitochondrial toxicity of these compounds as well.Type: ApplicationFiled: October 18, 2001Publication date: July 3, 2003Inventor: Lieven Stuyver
-
Publication number: 20030087873Abstract: The disclosed invention is a composition for and a method of treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug.Type: ApplicationFiled: October 18, 2001Publication date: May 8, 2003Inventors: Lieven Stuyver, Kyoichi Watanabe
-
Publication number: 20030077575Abstract: The present invention relates to a method for the rapid and reliable detection of drug-induced mutations in the reverse transcriptase gene allowing the simultaneous characterization of a range of codons involved in drug resistance using specific sets of probes optimized to function together in a reverse-hybridization assay.Type: ApplicationFiled: August 31, 2001Publication date: April 24, 2003Applicant: INNOGENETICS N.V.Inventors: Lieven Stuyver, Joost Louwagie, Rudi Rossau
-
Patent number: 6548244Abstract: The invention relates to a process for genotyping any HCV isolate present in a biological sample, previously identified as being HCV positive, and for classifying said isolate according to the percentage of homology with other HCV isolates, comprising the steps of: contacting said sample in which the ribonucleotides or deoxyribonucleotides have been made accessible, if need be, under suitable denaturation, with at least one probe from about 10 to about 40 nucleotides, with said probe being liable to hybridize to a region being in the domain extending from nucleotide at position −291 to nucleotide at position −66 of the 5′ untranslated region of one of the HCV isolates represented by their cDNA sequences, with said numbering of position beginning with the first ATG codon of the open reading frame encoding the HCV polyprotein, or with said probe being complementary to the above-defined probes, detecting the complexes possibly formed between said probe and the nucleotide sequence of the HCV iType: GrantFiled: July 6, 2001Date of Patent: April 15, 2003Assignee: Innogenetics N.V.Inventors: Geert Maertens, Lieven Stuyver, Rudi Rossau, Hugo Van Heuverswyn